Literature DB >> 23396588

Aggressive surgical resection of anaplastic thyroid carcinoma may provide long-term survival in selected patients.

Ryan F Brown1, Yadranko Ducic.   

Abstract

OBJECTIVE: In this study, we present our experience with aggressive surgical treatment in selected patients with anaplastic thyroid cancer with extrathyroidal extension. STUDY
DESIGN: Case series with chart review.
SETTING: Tertiary care referral center. SUBJECTS AND METHODS: Retrospective chart review of all patients with anaplastic thyroid cancer surgically treated by the senior author from January 1998 to July 2012.
RESULTS: A total of 38 cases of anaplastic thyroid cancer were treated (21 male and 17 female). The mean age was 64.5 years. Twenty-two patients were considered surgically unresectable (18 had distant metastases and 4 had extrathyroidal extension of cancer lateral to carotid arteries) and underwent biopsy with or without tracheostomy. The remaining 16 patients underwent surgical resection with curative intent. Fourteen of these patients underwent postoperative radiation therapy. None of these 16 patients developed local recurrence. Six developed distant metastasis at an average follow-up of 3.2 months, 1 died of an unrelated myocardial infarction at 3 months, 2 were lost to follow-up, and 7 remain disease free with an average follow-up of 4.8 years (range, 9 months to 8 years). Of those patients who underwent complete surgical resection followed by postoperative radiation, 7 of 14 (50%) are still alive, with a mean follow-up of 4.8 years.
CONCLUSION: Selected patients with anaplastic thyroid cancer with extrathyroidal extension (stage IVB) who show no distant metastases by computed tomography or positron emission tomography scans and who do not have tumor extending lateral to the carotid arteries are candidates for complete surgical resection.

Entities:  

Mesh:

Year:  2013        PMID: 23396588     DOI: 10.1177/0194599813477364

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  7 in total

1.  Airway issues in anaplastic thyroid carcinoma.

Authors:  Ashok R Shaha; Alfio Ferlito; Randall P Owen; Carl E Silver; Juan P Rodrigo; Missak Haigentz; William M Mendenhall; Alessandra Rinaldo; Robert C Smallridge
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-21       Impact factor: 2.503

2.  Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.

Authors:  Paul Weinberger; Sithara Raju Ponny; Hongyan Xu; Shan Bai; Robert Smallridge; John Copland; Ashok Sharma
Journal:  Thyroid       Date:  2016-12-15       Impact factor: 6.568

Review 3.  Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.

Authors:  Christina A von Roemeling; John A Copland
Journal:  Expert Opin Ther Targets       Date:  2015-09-28       Impact factor: 6.902

Review 4.  Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

Authors:  Vesna Bisof; Zoran Rakusic; Marija Despot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

5.  Treatment and Prognosis of Anaplastic Thyroid Carcinoma: A Clinical Study of 50 Cases.

Authors:  Tian-Run Liu; Zhi-Wen Xiao; Hai-Neng Xu; Zhen Long; Fan-Qin Wei; Shi-Min Zhuang; Xiao-Mei Sun; Liang-En Xie; Jia-Sheng Mu; An-Kui Yang; Guan-Ping Zhang; Yi Fan
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

6.  Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer.

Authors:  Mei-Chieh Chen; Yuan-Chin Tsai; Jen-Ho Tseng; Jr-Jiun Liou; Steve Horng; Heng-Ching Wen; Yu-Ching Fan; Wen-Bin Zhong; Sung-Po Hsu
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

Review 7.  The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer.

Authors:  Nerina Denaro; Cristiana Lo Nigro; Elvio G Russi; Marco C Merlano
Journal:  Onco Targets Ther       Date:  2013-09-16       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.